JP2024545293A - アミノピラゾール化合物の使用 - Google Patents

アミノピラゾール化合物の使用 Download PDF

Info

Publication number
JP2024545293A
JP2024545293A JP2024537401A JP2024537401A JP2024545293A JP 2024545293 A JP2024545293 A JP 2024545293A JP 2024537401 A JP2024537401 A JP 2024537401A JP 2024537401 A JP2024537401 A JP 2024537401A JP 2024545293 A JP2024545293 A JP 2024545293A
Authority
JP
Japan
Prior art keywords
compound
use according
formula
animal
dogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545293A5 (https=
Inventor
ホースプール，リンダ
コワルスキー，ティモシー
モーラー，クリスティーナ
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2024545293A publication Critical patent/JP2024545293A/ja
Publication of JP2024545293A5 publication Critical patent/JP2024545293A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024537401A 2021-12-24 2022-12-23 アミノピラゾール化合物の使用 Pending JP2024545293A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217736 2021-12-24
EP21217736.4 2021-12-24
PCT/EP2022/087698 WO2023118555A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Publications (2)

Publication Number Publication Date
JP2024545293A true JP2024545293A (ja) 2024-12-05
JP2024545293A5 JP2024545293A5 (https=) 2026-01-05

Family

ID=79025165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537401A Pending JP2024545293A (ja) 2021-12-24 2022-12-23 アミノピラゾール化合物の使用

Country Status (9)

Country Link
US (1) US20250049775A1 (https=)
EP (1) EP4452970A1 (https=)
JP (1) JP2024545293A (https=)
KR (1) KR20240124925A (https=)
CN (1) CN118541364A (https=)
AU (1) AU2022418280A1 (https=)
CA (1) CA3242449A1 (https=)
MX (1) MX2024007863A (https=)
WO (1) WO2023118555A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
CA2849168A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
JP7116063B2 (ja) 2016-12-14 2022-08-09 インターベット インターナショナル ベー． フェー． 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
KR20220119024A (ko) * 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물

Also Published As

Publication number Publication date
WO2023118555A1 (en) 2023-06-29
KR20240124925A (ko) 2024-08-19
EP4452970A1 (en) 2024-10-30
AU2022418280A1 (en) 2024-06-13
US20250049775A1 (en) 2025-02-13
CN118541364A (zh) 2024-08-23
CA3242449A1 (en) 2023-06-29
MX2024007863A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
JP2025092508A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
WO2013068371A1 (en) Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
JP2020529995A (ja) 行動の変化の治療方法
RU2679631C2 (ru) Композиции грапипранта и способы их применения
JP2024545293A (ja) アミノピラゾール化合物の使用
ES2358931T3 (es) Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos.
JP7500600B2 (ja) プレガバリン製剤およびその使用
KR102419769B1 (ko) 약물 조성물
CN108078984A (zh) 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
RU2706700C1 (ru) Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях
JP2020530462A (ja) 治療製剤およびその使用
RU2799049C2 (ru) Способы лечения изменений поведения
Singh et al. Pain Mitigation Strategies for Disbudding in Goat Kids. Animals 2024, 14, 555
US20080199520A1 (en) S-Adenosyl-L-Methionine for Regulating Behavioral Disorders in Pets
RU2811411C2 (ru) Композиции грапипранта и способы их применения
HK40060289A (en) Pregabalin formulations and use thereof
EP3763365A1 (en) Aroylimidazolones for the treatment of thaumetopoea exposure
NZ724007B2 (en) Compositions of grapiprant and methods for using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251219